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Autosomal-Dominant Distal Myopathy Associated
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Klaus Zerres,2 Hanns Lochmu¨ller,10 Eric Seboun,11 Joachim Weis,12 Jacques S. Beckmann,13
Michael A. Hauser,4 and Charles E. Jackson14
Distal myopathies represent a heterogeneous group of inherited skeletal muscle disorders. One type of adult-onset, progressive auto-
somal-dominant distal myopathy, frequently associated with dysphagia and dysphonia (vocal cord and pharyngeal weakness with distal
myopathy [VCPDM]), has been mapped to chromosome 5q31 in a North American pedigree. Here, we report the identiﬁcation of
a second large VCPDM family of Bulgarian descent and ﬁne mapping of the critical interval. Sequencing of positional candidate genes
revealed precisely the same nonconservative S85C missense mutation affecting an interspecies conserved residue in theMATR3 gene in
both families.MATR3 is expressed in skeletal muscle and encodesmatrin 3, a component of the nuclear matrix, which is a proteinaceous
network that extends throughout the nucleus. Different disease related haplotype signatures in the two families provided evidence that
two independent mutational events at the same position inMATR3 cause VCPDM. Our data establish proof of principle that the nuclear
matrix is crucial for normal skeletal muscle structure and function and put VCPDM on the growing list of monogenic disorders associ-
ated with the nuclear proteome.The distal myopathies are a clinically and pathologically
heterogeneous group of genetic disorders in which the
distal muscles of the upper and the lower limbs are selec-
tively or disproportionately affected.1,2 Comparison of
the different forms of distal myopathy has shown consid-
erable phenotypic variability, both in terms of the age at
onset and the pattern of muscle involvement. Some
subtypes of distal myopathy clinically or genetically over-
lap with the inclusion body myopathies (summarized in
MIM 605637 for IBM3) and the limb-girdle muscular
dystrophies (summarized in MIM 159000 for LGMD1A
and MIM 253600 for LGMD2A). Distal myopathies are
caused bymutations in genes encoding proteins associated
with the plasma membrane (dysferlin [MIM 603009]3,4
and caveolin-3 [MIM 601047]5), with the sarcomere (titin
[MIM 188840]6 and myosin [MIM 160760]7), and with
posttranslational protein modiﬁcations (UDP-N-acetylglu-
cosamine-2-epimerase [MIM 603824]).8
A decade ago, we described in this journal an adult-onset
autosomal-dominant distal myopathy often complicated
by vocal cord paralysis (vocal cord and pharyngeal weak-
ness with distal myopathy, VCPDM [MIM 606070]).9
Genome-wide linkage analysis in a single large North
American pedigree revealed that the VCPDM locus map-ped to a 12 cM (11.8 Mb) interval on chromosome 5q
betweenmicrosatellite markers D5S1995 and D5S436. First
symptoms developed at the age of 35–57 years and the
most frequent initial manifestation was ankle dorsiﬂexion
weakness and foot drop. The disease had a slowly progres-
sive course with involvement of the feet and hands and
eventually an effect on shoulder and pelvic muscles. Vocal
cord or swallowing dysfunction occurred in most cases.
Electromyogram (EMG) and nerve conduction studies
indicated a myopathy, and the levels of serum creatine
phosphokinase (CPK) were usually only mildly or moder-
ately elevated (at maximum 83 the upper limits of
normal). Analysis of muscle biopsies showed myopathic
changes including variations in ﬁber size, ﬁber splitting,
and subsarcolemmal rimmed vacuoles.
We were now able to expand the family because another
two siblings were now deﬁnitely afﬂicted with the disease.
These individuals belong to an additional branch of the
family and had not been included in the 1998 paper (for
a comparison of clinical data, see Table 1). Analysis of mi-
crosatellite markers and haplotype reconstruction dis-
closed a critical recombination event between D5S2009
and D5S21116 in both patients. On the basis of the avail-
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Table 1. Comparison of Clinical Features
Distal weakness
Family Patient
Age at
Onset
(years) First Symptom Legs Hands
Shoulder
Weakness
Swallowing/
Vocal Cord
Dysfunction CPK
NAa Mean: 45
(Range: 35–57)
Legs: 7/11 Hands: 2/11
Pharyngeal: 2/11
12/12 10/12 4/12 9/12 Normal, 83
NA DM73.3 48 Legs þ þ   23
NA DM73.4 45 Legs þ þ  þ 23
BG IV.9 43 Legs þ þ   ND
BG V.6 47 Legs þ þ þ þ ND
BG V.9 40 Legs þ þ þ þ 23
BG V.11 54 Legs þ þ  ND ND
BG V.13 52 Legs þ þ  ND ND
BG V.15 42 Legs þ   ND ND
BG V.17 46 Hands  þ  ND ND
BG V.23 49 Legs þ þ þ  43
BG V.27 40 Legs þ þ þ þ 33
BG V.30 36 ND þ   ND 23
NA, North American family; BG, Bulgarian family; ND, not determined; CPK, creatine phosphokinase;
a Data summarized from Feit et al.9additional densely spaced short tandem repeat (STR) poly-
morphisms was deduced. Using these markers, we mapped
the recombination event between AC008667A and
AC008667C, thereby reducing the candidate interval
from 11.8 Mb to 5.9 Mb. By using newly established
STRs, we could also narrow down the site of the recombi-
nation at the centromeric border of the VCPDM region.
The reﬁned critical region spanned 5.37 Mb between STR
markers sara2AC and AC008667C (Figure 1, for details
referring to newly established STR markers, see Table S1
available online). We then checked a series of ten families
with autosomal-dominant distal myopathy with clinical
features resembling VCPDM for compatibility with linkage
to the VCPDM region on chromosome 5q31.We identiﬁed
a multigenerational Bulgarian family (Figure 2) with a
typical VCPDM phenotype (for a comparison of clinical
data, see Table 1). With a set of 12 available DNA samples
from this family, genotyping and haplotype reconstruc-
tion of STR markers D5S458, D5S500, D5S594, and
D5S2116 established linkage to the VCPDM interval. A
maximum two-point LOD score (Zmax) of 3.35 was ob-
tained at recombination fraction (q) 0 for marker
D5S500, but no new recombination events, allowing
a further restriction of the VCPDM interval, were identi-
ﬁed. VCPDM-disease-associated haplotypes differed
between the North American and Bulgarian samples. The
review board for medical ethics at Aachen University of
Technology gave approval for sample collection and
molecular genetic studies in conjunction with local
approval in the United States and Bulgaria.
The May 2004 version of the human genome assembly
displayed 56 genes represented in the NCBI Reference
Sequence (RefSeq) collection between the newly estab-
lished borders of the VCPDM critical region. The most
apparent candidate gene within this interval was myotilin512 The American Journal of Human Genetics 84, 511–518, April 10(MYOT [MIM 604103]). Myotilin contributes to sarcomere
assembly and promotes actin crosslinking and sarcomeric
integrity,10 and MYOT mutations have been shown to
cause Limb-Girdle Muscular Dystrophy Type 1A
(LGMD1A),11 a small fraction of myoﬁbrillar myopathy
cases (MFM [MIM 609200]),12 and spheroid body myop-
athy [MIM 182920].13 However, we found noMYOTabnor-
malities on the genomic, transcript, and protein level in
the North American VCPDM family.14 Moreover, no
MYOT mutation was detected in the Bulgarian pedigree
Figure 1. Refinement of the VCPDM Interval in the North
American VCPDM Family
A subset of markers used in this study is given in centromeric to
telomeric orientation. The physical map positions are according
to the UCSC March 2006 freeze. Patient V.34 carries the full-blown
disease haplotype. Recombination events in patient V.37 and
patient DM73.3 (newly identified patient from the North American
family) excluded markers sara2AC and AC008667C (printed in red),
respectively, delimiting a 5.37 Mb region., 2009
Figure 2. Pedigree of the Bulgarian VCPDM Family
Individuals of whom DNA samples were available are marked by asterisks.by sequencing of all coding exons. These results provided
strong evidence that myotilinopathies and VCPDM are
not allelic disorders. Therefore, we prioritized the remain-
ing annotated sequences with respect to skeletal muscle
biology and disease. We used information from publicly
available databases and characterized proteins in silico by
BLAST alignments to protein database entries and by
comparison of domain composition and organization
with the SMARTalgorithm.We also investigated positionalcandidate genes for structural and functional homology
with the known proteins involved in distal myopathies
and related disorders. The entire coding and adjacent in-
tronic regions of 20 candidate genes for a distal myopathy
were analyzed by direct sequencing (Table 2).
We detected the same c.254C/G change in both fami-
lies in exon 2 of the MATR3 gene (MIM 164015)
(Figure 3A, for primer sets used to analyze the MATR3
gene, see Table S2), whereas no pathogenic mutationsTable 2. Positional Candidate Genes Analyzed
Genomic Position
Gene Name Expression in Skeletal Muscle Entrez Gene Identifier OMIM Number Strand Start End
Number of
Coding Exons
SEC24A þ 10802 607183 þ 134012378 134091500 23
C5orf14 þ 79770  þ 134237359 134265222 5
DCOHM þ 84105 609836 þ 134268709 134326235 4
LOC153328 unknown 153328  þ 135198264 135236335 6
FBXL21 þ 26223 609087 þ 135300162 135305266 4
SPOCK þ 6695 602264  136338886 136862917 10
KLHL3 þ 26249 605775  136981088 137099678 15
C5orf5 þ 51306 609371  137301541 137396701 21
BRD8 þ 10902 602848  137520472 137542257 29
C5orf6 þ 51307 609372 þ 137701603 137713315 4
C5orf7 þ 51380 609373 þ 137716184 137800615 24
HSPA9B þ 3313 600548  137918923 137939014 17
SIL1 þ 64374 608005  138310309 138561964 9
MATR3 þ 9782 164015 þ 138657254 138694029 14
PAIP2 þ 51247 605604 þ 138705418 138733308 3
PACAP þ 51237 609447  138751156 138753504 4
DNAJC18 þ 202052   138775279 138803038 8
TMEM173 þ 340061 612374  138835733 138842476 6
UBE2D2 þ 7322 602962 þ 138920935 138988202 7
PSD2 þ 84249  þ 139155590 139204232 14
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were identiﬁed in any of the other candidate genes. This
mutation leads to an amino acid substitution from serine
to cysteine at position85 (S85C).Weconﬁrmed segregation
A
B
C
Figure 3. Identification of the VCPDM Mutation
(A) DNA sequence traces illustrating the c.254C/G, S85C muta-
tion in the MATR3 gene (upper panel) and the corresponding
wild-type sequence (lower panel). The position of the single nucle-
otide exchange is marked with an arrowhead.
(B) Comparison of disease-associated haplotypes. The disease-
associated haplotype in the North American family is shown under
the column heading ‘‘NA’’; the disease-associated haplotype in the
Bulgarian pedigree is shown under the heading ‘‘BG.’’ The phases of
alleles have been determined for all markers. Intragenic markers
and the mutation in exon 2 of the MATR3 gene are boxed. The
closest flanking and intragenic markers that show different alleles
for the North American and Bulgarian samples are printed in red.
(C) Multiple sequence alignment of human matrin 3 and related
sequences. The mutant serine 85 residue is marked by an arrow-
head.514 The American Journal of Human Genetics 84, 511–518, April 10of this change in both families. Thismutation has not been
deposited in the most recent release (build 129) of dbSNP,
and572healthy controls (300German, 164whiteNorthern
American, and 108 Bulgarian) were negative for this nucle-
otide substitution. Analysis of haplotypes for closely ﬂank-
ing and intragenic SNP and STR markers showed no
evidence of haplotype sharing between the North Amer-
ican and the Bulgarian VCPDM families (Figure 3B, for
details referring to SNP and STR markers used, see Table
S1). This indicates that these two kindreds with VCPDM
are not closely related and suggests that the same MATR3
mutation arose independently in each of them.
Matrin 3 is a 130 kDA (847 amino acid) nuclear protein
with nuclear import and export motifs and several binding
sites for DNA and RNA15,16 (Figure S1A). Matrin 3 is highly
conserved through evolution (96% sequence homology
between human and rat orthologs) and expression is
observed in a variety of tissues including skeletal muscle
and lymphoblasts (HUGE protein database and Figures
S1B and S1C). Matrin 3 is a component of the nuclear
matrix, an insoluble network that is dispersed throughout
the nucleus and that is operationally deﬁned as being resis-
tant to high salt or detergents.17 Although the nature of the
nuclearmatrix is still under debate,18 it has achieved prom-
inence given that its components are associated with the
protein machinery for transcription, RNA splicing, and
DNA replication.19 Moreover, accumulating experimental
evidence suggests that the positioning of individual chro-
mosomes in the interphase nucleus20 is achieved by attach-
ment of chromatin loops to the nuclear matrix at the
so-calledmatrix attachment regions (MARs).21,22 Although
experimental evidence for a causal relationship is still
lacking, the 3D organization of the genome in the inter-
phase nucleus is believed to be an important factor for
the orchestration of gene expression in the mammalian
genome.23
The nuclear matrix is structurally and functionally con-
nectedwith the nuclear lamina, the nuclear proteome asso-
ciated with the inner leaﬂet of the nuclear envelope.24–26
The role of the nuclear lamina in human diseases has
been established during the last 15 years,27 and the growing
list of diseases of the nuclear envelope also includes neuro-
muscular conditions such as Emery Dreyfuss muscular
dystrophy (MIM 310300; MIM 181350),28,29 limb-girdle
muscular dystrophy type 1B (MIM 159001),30 and Char-
cot-Marie-Tooth neuropathy type 2B1 (MIM 605588).31
Additional evidence for a role of the nuclear matrix in the
pathophysiology of the skeletal muscle comes from very
recent work on facio-scapulo-humeral dystrophy (FSHD
[MIM 158900]) and X-linked myopathies. First, the partial
deletion of theD4Z4 repeat array that causes FSHD32 results
in delocation of an adjacent MAR from the nuclear matrix.
This alteration is expected to change chromatin structure
and to release transcriptional repression of neighboring
genes implicated in the genesis of FSHD.33 Second, muta-
tions in theFHL1gene (MIM300163), encoding four-and-a-
half LIM domain 1, cause clinically variable types of, 2009
X-linkedmyopathies (MIM300695).34–36 FHL2, a homolog
of FHL1, has been reported to bind to the nuclear matrix
protein NP220 and the splicing factor PSF, a knownmatrin
3 interaction partner.37,38
Currently, the effect of the identiﬁed S85C alteration on
matrin 3 structure and function is not clear. Alterations of
amino acid residues involved in nucleic acid binding may
seriously impair the matrin 3 function. But the residues in
contact with RNA and DNA are not close to the position
shown here as changed (Figure S1A). However, assessment
of thebiochemical severityof the S85Cchangeand the loca-
tion and context of the altered amino acid in the protein
sequence suggests that the mutation has functional conse-
quences. With the Grantham scale,39 which categorizes
codon replacements into classes of chemical dissimilarity
between the encodedaminoacids, the c.254C/Gmissense
mutation in matrin 3 was designated to be moderately
radical according to the classiﬁcation proposed by Li
et al.40 Given that disease-causing mutations are likely to
occur at regions encoding conserved amino acid residues
across species,41 we studied cross-species conservation
of regions surrounding the S85C alteration by using the
ClustalW algorithm. We found that the residue S85 is
conservedacrossawiderangeof species includingmammals,
chicken, frog, and ﬁsh (Figure 3C). Further, we applied three
in silico algorithms—the SIFT algorithm,42 the PolyPhen
algorithm,43 and the subPSEC algorithm44,45—to predict
the putative effect of the mutation on the protein. With
SIFT, the S85C substitution was classiﬁed as intolerant ac-
cording to the classiﬁcation byNg andHenikoff.42 PolyPhen
designated the S85C alteration as possibly damaging accord-
ing to the classiﬁcation by Xi et al.46 Finally, the subPSEC
program predicted the S85C change to cause a deleterious
effect on protein function with the criteria proposed by
Brunham et al.47
We had the opportunity to study a muscle biopsy of
a Bulgarian VCPDM case. Morphological analysis of the
frozen muscle biopsy specimen revealed end-stage myop-
athy. The muscle was largely replaced by proliferated fat
and connective tissue (Figure 4A). We observed strikingly
variable degrees of immunoreactivity of myonuclei for ma-
trin 3 (Figures 4B and 4C), whereas all nuclei of a normal
control muscle were strongly labeled after incubation
with the matrin 3 antibody (Figure 4D). Autophagic vacu-
oles were encountered in several muscle ﬁbers and myonu-
clei displayed various stages of nuclear degeneration
(Figures 4E–4G). On the other hand, nuclei of cultured
lymphoblasts obtained from a VCPDM patient did not
disclose overt pathology (Figure S2A). However, fraction-
ation of nuclear proteins showed that matrin 3 is almost
exclusively conﬁned to the insoluble fraction in VCPDM
lymphoblasts, whereas in control lymphoblasts, a consid-
erable proportion of matrin 3 occurs in the nucleic-acid
binding protein fraction (Figure S2B). A similar shift of
the subnuclear distribution was seen for the Myc-tagged
S85C matrin 3 mutant compared to Myc-tagged wild-
typematrin 3 upon overexpression in Cos7 cells. Immuno-The Amﬂuorescence analysis of transfected matrin 3 in Cos7 cells
ascertained that this observation did not arise from the
formation of insoluble nuclear aggregates (Figures S2C
and S2D). Although the present data suggest that muscle
pathology in VCPDM might be related to changes of the
matrin 3 expression level and/or intranuclear mobility
functional studies are obviously needed to clarify how
mutant matrin 3 affects skeletal muscle physiology.
A variety of mechanisms leading to myoﬁber degenera-
tion could be involved inVCPDMpathogenesis: (1)modiﬁ-
cation of gene expression relative to abnormal chromatin
organization: matrin 3 has been shown to regulate tran-
scription rates through associationwithmatrix attachment
sites in vitro.48 (2) Deregulation of nuclear mRNA export:
together with p54nrb and PSF, matrin 3 controls the reten-
tion of hyperedited mRNAs in the nucleus to prevent their
translation at the ribosome.49 (3) Abnormal pre-mRNA
splicing: matrin 3 was found to be coimmunoprecipitated
with hLodestar/HuF2, together with CDC5L, hnRNP A1,
hnRNP A2/B1, and chromokinesin, suggesting it is also
involved in pre-mRNA splicing.50,51 (4) Alterations of the
nuclear proteome: matrin 3 also plays a role in the nuclear
import of proteins,52 thereby potentially altering nuclear
functions. As a matter of course, these putative disease
mechanisms are not necessarily mutually exclusive.
To our knowledge, this study is the ﬁrst report of the
association of a mutation in a gene encoding a nuclear
matrix protein with a human hereditary disease. Our
observations of the same MATR3 gene mutation in two
unrelated kindreds with VCPDM that results in a noncon-
servative substitution of an interspecies conserved amino
acid and that was absent in control subjects strongly
support the pathogenic signiﬁcance of this mutation.
Our discovery ofMATR3mutations as the cause of VCPDM
will aid genetic testing and counselling of patients with
distal myopathies. Moreover, the knowledge about the
involvement of the nuclear matrix protein matrin 3 in
an inherited myopathy provides a path to a better under-
standing of the development, degeneration, and regenera-
tion of skeletal muscle. Identiﬁcation of the underlying
mechanisms of muscle ﬁber damage in inherited myopa-
thies may hold promise for the development of thera-
peutic interventions in these (usually rare) entities and,
perhaps, in the (usually more frequent) sporadic forms of
skeletal muscle disorders. In this way, our data are relevant
for patient and family care, for basic science, and—hope-
fully—future options to treat neuromuscular disorders.
Supplemental Data
Supplemental Data include two ﬁgures and two tables and can be
found with this article online at http://www.ajhg.org/.
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F G
E
B C Figure 4. Muscle Biopsy Findings in
VCPDM
The muscle biopsy specimen was taken from
the left M. gastrocnemius of a 54-year-old
male patient of the Bulgarian family.
(A) The muscle parenchyma is largely
replaced by fat and connective tissue. The
remaining muscle fibers show a high degree
of caliber variability. Hypertrophic muscle
fibers containing nonsubsarcolemmal nuclei
are marked by arrows. A hematoxylin stain
was used on the cryostat section. The scale
bar represents 250 mm.
(B and C) Matrin 3 immunostaining (rabbit
anti-matrin 3 antibody BL2526; Bethyl
Labs, Montgomery, TX, USA) of cryosec-
tioned muscle fibers showing variable
degrees of immunoreactivity of myonuclei
(black arrows, immunoreactive nuclei
labeled by brown reaction product; white
arrows, faintly stained or almost unlabelled
myonuclei). Because of the vast prolifera-
tion of fat tissue, the cryostat sections
had to be cut much thicker than normal,
15 mm, resulting in a blurry appearance of
the nuclei. A hematoxylin counterstain
was used. The scale bar represents 40 mm
in (B) and 25 mm in (C). The inset in (C)
shows a muscle fiber with intact sarco-
lemmal dystrophin immunoreactivity (Dys
1 antibody, Novocastra, Newcastle, UK)
indicating preserved overall immunoreac-
tivity of the biopsied tissue. The scale bar
represents 50 mm.
(D) Normal control muscle immunostained
with the matrin 3 antibody: Strong immu-
noreactivity of all myonuclei. A hematoxylin counterstain was used on the cryostat section. The scale bar represents 50 mm.
(E) Semithin section of biopsy tissue that was cut from the block of frozen tissue, thawed, fixed in 6% buffered glutaraldehyde, and
embedded in epoxy resin. Two muscle fibers are surrounded by fibrotic connective tissue and fat cells. Dark, osmiophilic material has
accumulated in both fibers. The arrow indicates a strongly osmiophilic deposit, most likely autophagic material. A paraphenylene diamine
stain was used. The scale bar represents 20 mm.
(F and G) Electron microscopy of ultrathin sections of the resin-embedded tissue. In (F), this muscle fiber shows an irregularly shaped
nucleus with loose chromatin and numerous small perinuclear autophagic vacuoles containing osmiophilic, often myelin-like material.
The scale bar represents 3 mm. In (G), two irregular, preapoptotic myonuclei are shown. One of the nuclei embraces an autophagic vacuole
(indicated by an arrow), probably as a result of sarcoplasmic invagination. The scale bar represents 2 mm.Heisenberg fellow and C. Stendel is a postdoctoral fellow of the
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European Bioinformatics Institute Web site (for ClustalW), http://
www.ebi.ac.uk/index.html
GeneCards Human Gene Database (for data on positional candi-
date genes), http://www.genecards.org
HUGE protein database (for matrin 3 [KIAA0723]), http://www.
kazusa.or.jp/huge/index.html
Human genome assembly (for chromosome 5q31), http://
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NCBI blast server (for protein sequence alignments), http://blast.
ncbi.nlm.nih.gov/Blast.cgi, 2009
NCBI dbSNP repository (for single-nucleotide polymorphisms),
http://www.ncbi.nlm.nih.gov/SNP
PolyPhen algorithm (for prediction of the S85C mutation effect),
http://genetics.bwh.harvard.edu/pph/
SIFTalgorithm (for prediction of the S85Cmutation effect), http://
blocks.fhcrc.org/sift/SIFT.html
SMART program (for the analysis of protein domain structure and
composition), http://smart.embl-heidelberg.de
subPSEC algorithm (for prediction of the S85C mutation effect),
http://www.pantherdb.org/tools/csnpScoreForm.jsp
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